Tempus AI (TEM) said Wednesday it entered a multi-year collaboration with Genialis to advance the development and validation of RNA-based biomarker algorithms for cancer treatment.
Financial details weren't disclosed.
Genialis will leverage Tempus' multimodal dataset to validate its AI foundation model, which is based on data from around 1 million RNA-sequencing samples.
Through this partnership, Genialis can now use Tempus' multimodal dataset and analytics platform, Lens, to access de-identified patient records and tools for signature validation, aiding in the market launch of its clinical algorithms.
Tempus, in turn, gains the right to evaluate and potentially license these algorithms for use in its xR platform, the company said.
Shares of Tempus were down 2.1% in recent trading.
Price: 38.06, Change: -0.81, Percent Change: -2.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。